Clinical Trial Update: Study to Demonstrate Cognitive Enhancing Effects of BF2.649 [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the cognitive enhancing effects of BF2.649 in schizophrenia has completed, with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• BF2.649 (BF2.649)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED | Results posted: 2019-04-23